Rachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center

Articles

The Investigational Pipeline for Advanced BTC

May 30th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.

Factoring in Trastuzumab Deruxtecan in the Advanced BTC Setting

May 30th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss how to factor in trastuzumab deruxtecan in advanced biliary tract cancer.

Considering Factors When Choosing Among IO Agents in Advanced BTC

May 30th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss considering factors for immunotherapy agents in advanced biliary tract cancer.

Clinical Implications of 3-Year OS Data With Durvalumab/Chemo in Advanced BTC

May 29th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the clinical implications of 3-year survival data from TOPAZ-1 in advanced biliary tract cancer.

Putting TOPAZ-1 Data into Context for Patients With Advanced BTC

May 29th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient put the TOPAZ-1 data into context for patients with advanced biliary tract cancer.

Homing in on the TOPAZ-1 Trial in Biliary Tract Cancer

May 29th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.

Discussion of a Patient Case of Advanced BTC

May 29th 2024

Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, discuss a case of advanced biliary tract cancer with a patient.

Prognosis and Standards of Care in Advanced Biliary Tract Cancer

May 29th 2024

Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, and a patient discuss prognosis and standard-of-care treatment for patients with advanced biliary tract cancer.

The Future of HCC Treatment

August 9th 2023

The panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.

Safety Profiles of Available Therapies in Advanced HCC

August 9th 2023

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

Optimal Sequencing in Patients With Advanced HCC

August 3rd 2023

Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.

Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study

August 3rd 2023

Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.

Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

July 28th 2023

Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.

The Role of Adjuvant Therapy in Patients With Early-Stage HCC

July 28th 2023

Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.

Treatment Approaches for Patients With Early-Stage HCC

July 19th 2023

Manish Shah, MD, details the role of locoregional therapy in HCC, and Julio Gutierrez, MD, comments on transplant as a curative option.

Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC

July 19th 2023

The panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.

Diagnosing Patients With Hepatocellular Carcinoma

July 12th 2023

Key opinion leaders review the process of diagnosing HCC, the role of molecular testing, and associated challenges.

Overview of Hepatocellular Carcinoma (HCC)

July 12th 2023

Experts provide an overview of hepatocellular carcinoma, including the risk factors and prognosis.

The Evolving Treatment Landscape of Biliary Tract Cancers

March 22nd 2023

Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.

Novel Targeted Therapies Under Investigation in Biliary Tract Cancers

March 22nd 2023

Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.